他汀类药物防治卒中研究进展.PDFVIP

322 2009 6 18 6 6 Chin J Cerebrovasc D is, Jun18, 2009, Vol6, N o6 陈雅琴 赵水平 : ; ; do :i 103969/jissn1672-5921200906012 + : R 181. 3 5; R743 : A , ; , , , , 1 , 1. 1 1. 2 , , 4% ~ 8% , , , 20% 5 ( Cholesterol An R ecurrent Events, , CARE), (The Stroke Prevention by Aggressive Re uction in 4159, (TG) Cholesterol Levels , SPARCL ) [ 5] 6. 22mmol/L,( LDL-C) SPARCL 4731 , , 5( 4. 62), 6 TIA; LDL-C 2. 6 ~ 32%, 4. 9mmol/L; ( transient ischem ic attack, T IA ) 80mg/ , 4. 9SPARCL [ 1] , , 27%, 16%; , , 43% , [ 5] TIA , ( Collaborative A torvastatin Diabetes Stu y, CARDS) 2 [ 2] , 2 ( 10mg/ ), , 48% , 14 90 056 ( Cholesterol T reatment 2. 1 Trialists, CTT ) , 5 C( h igh-sensitivity C- [ 3] [ 4] reactive protein, hs-CRP) 21% , H enyan [ 6] , R i ker 17 802 hs-CRP ( hs-CRP 20 mg/L ) ( LDL-C : 3. 4mmol/L, 130mg / l) ( 20mg / ), 1. 9 : 410011, , hs-CRP 37% 2009 6 18 6 6 Chin J Cerebrovasc D is, Jun18, 2